Summary

The Medicines Patent Pool (MPP) is revising its existing impact methodology and is seeking proposals from companies to support this process and lead on a pilot project to enable measurement of its impact along different public health scenarios.

The MPP currently measures impact in terms of total savings from the procurement of more affordable medicines, number of patient-years (HIV) and patients (HCV) served through MPP licences, total number of doses supplied by MPP’s generic partners, total new countries that benefitted from MPP’s licence agreements, countries where medicines were made available for the first time through the MPP’s work, total countries where MPP licensees have sold and average price drop since MPP licences. The MPP now wishes to revisit its methodology to enable the measurement of its impact along different scenarios initially for two key medicines: Dolutegravir (DTG) and Daclatasvir (DAC).

About the Medicines Patent Pool

The Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to, and facilitate the development of, life-saving medicines for low- and middle-income countries. Through its innovative business model, the MPP partners with civil society, governments, international organisations, industry, patient groups and other stakeholders, to prioritise and license needed medicines and pool intellectual property to encourage generic manufacture and the development of new formulations. To date, the MPP has signed agreements with nine patent holders for thirteen HIV antiretrovirals, one HIV technology platform, three hepatitis C direct-acting antivirals and a tuberculosis treatment. The MPP was founded by Unitaid, which serves as sole funder for the MPP’s activities in HIV, hepatitis C and tuberculosis. The MPP is now expanding its activities to cover Essential Medicines, which requires engagement with many new stakeholders, including potential funders.

For more information, please click here.


Scope of work

  • Take both products as pilots – the methodology should be developed using DTG and then applied to DAC.
  • Examine and agree on the most appropriate counterfactuals for each within a conceptual framework that will facilitate using the methodology for other MPP licensed products.
  • Examine and agree on the most appropriate methodology for measuring economic, human[1] and public health impact that can also be used for other MPP licensed products, using readily available data and/or validated models.
  • Apply the methodology to the products in question, quantify impact and prepare a report describing the impact.
  • Examine best practice amongst the global health community and, as far as possible, ensure the pilots align with it. In particular, the methodology should align with Unitaid’s impact framework.
  • Ensure that the impact is easy to communicate to a lay audience, as well as potential funders and the global public health community.
  • Work closely at all stages with MPP and Unitaid and possibly other relevant stakeholders such as other Unitaid’s grantees to align on assumptions.
  • Project manage all of the above.

Deliverables and timeline

  • Inception report
  • A draft methodology including:
  • a methodology for choosing counterfactuals
  • a methodology for assessing impact (projected and to date based on actual data)
  • the impact results of the 1 or 2 pilots
  • Final report and comprehensible excel (or automated) model completed by March 31, 2020 

Profile of consultant

Essential skills:

  • Strong economic impact analysis skills;
  • Strong public health impact analysis skills;
  • Knowledge and experience of Global health;
  • Excellent stakeholder management capability;
  • Excellent communication skills, with a flair for presenting compelling arguments using evidence and analysis;
  • Professional proficiency in English.

Desirable skills:

  • Impact analysis of HIV/AIDS, HCV and TB interventions;
  • Prior experience of working with Unitaid and The Global Fund and other key stakeholders in the HIV/AIDS, HCV and TB space.

Place of work and frequency of interaction: a combination of office based and remote work to be defined. 


Application process

Proposals to be submitted no later than 19 July 2019 to recruitment@medicinespatentpool.org

For any questions and clarifications, please write to Esteban Burrone at eburrone@medicinespatentpool.org and Sébastien Morin at smorin@medicinespatentpool.org.

Proposals must include a presentation of your company, relevant experience, type of services, fees and proposed timeline for deliverables including an estimated number of hours/days/weeks for this consultancy.

Evaluation criteria of received proposals are as follows:

  • Requirements fulfilment
  • Experience and scope of expertise
  • Cost effectiveness
  • Support availability

Working language: English

[1] For the purpose of this work, human impact is meant to measure outcomes such as fewer side effects, reduction in fear of developing AIDS, emotional well-being of not having to change regimen (versus emotional toll of having to change, e.g. because resistance to efavirenz has developed), convenience of one pill a day, knowing you’re on the best treatment available anywhere in the world (i.e. you are as important as anyone else) – all of which might be very difficult to measure in either public health or economic terms.

This website uses cookies to ensure you get the best experience on our website. Learn More